Subrat K Acharya1, Ramesh Kumar2, Gangadhar Bharath3, Gyanranjan Rout4, Deepak Gunjan4, Baibaswata Nayak4. 1. Department of Gastroenterology, Fortis Hospital, Vasant Kunj, New Delhi, India. 2. Department of Gastroenterology, All India Institute of Medical Sciences, Patna, India. 3. Department of Medicine, All India Institute of Medical Sciences, New Delhi, India. 4. Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Abstract
BACKGROUND/ OBJECTIVES: Acute liver failure (ALF) is rare and associated with poor outcomes. The outcomes of ALF and predictors of outcome may vary as per the etiology. There are limited data on the predictors of spontaneous survival among patients with ALF of non-A-E hepatitis or cryptogenic etiology. We aimed to assess clinical course, complications, and outcome of non-A-E etiology ALF. METHODS: In this prospective analysis, all consecutive ALF patients (n = 1555; January 1986-June 2018) were analyzed. Non-A-E-ALF was defined as ALF that could not be attributed to known etiologies such as drugs, viral hepatitis, autoimmune hepatitis, and Wilson's disease. Clinical course, complications, and outcomes of non-A-E-ALF patients who did not undergo liver transplantation were analyzed. Unadjusted and adjusted odds ratios (ORs) were calculated. RESULTS: Non-A-E-ALF constituted 34.6% (n = 538) of all ALF patients, whereas hepatitis E virus (HEV), hepatitis B virus (HBV), and anti-tuberculosis therapy (ATT) accounted for 29.5% (n = 459), 8.6% (n = 134), and 7.4% (n = 115), respectively. Among non-A-E-ALF patients, mean age was 28.8 ± 12.0 years, 50.9% females, majority (63.1%) had hyperacute presentation, and 79.2% had advanced encephalopathy at presentation. The frequency of cerebral edema in non-A-E-ALF (53.3%) was higher than that in HEV-ALF (41.2%) and ATT-ALF (44.2%), P < 0.001. The survival rate in non-A-E-ALF (37.5%) was poorer than HEV-ALF (54.9%) and was comparable to that in HBV (35.8%) and ATT (29.6%) induced ALF. The baseline prothrombin time prolongation (odds ratio [OR] 1.041; 95% confidence intervals [CI], 1.017-1.065) and infection (OR 2.366; 95%CI, 1.107-5.055) were independent predictors of outcome in non-A-E-ALF. The 3-days acute liver failure early dynamic model had the best value in predicting the outcome. CONCLUSIONS: Non-A-E-ALF accounts for one-third of all cases of ALF and is associated with poor spontaneous survival.
BACKGROUND/ OBJECTIVES: Acute liver failure (ALF) is rare and associated with poor outcomes. The outcomes of ALF and predictors of outcome may vary as per the etiology. There are limited data on the predictors of spontaneous survival among patients with ALF of non-A-E hepatitis or cryptogenic etiology. We aimed to assess clinical course, complications, and outcome of non-A-E etiology ALF. METHODS: In this prospective analysis, all consecutive ALF patients (n = 1555; January 1986-June 2018) were analyzed. Non-A-E-ALF was defined as ALF that could not be attributed to known etiologies such as drugs, viral hepatitis, autoimmune hepatitis, and Wilson's disease. Clinical course, complications, and outcomes of non-A-E-ALF patients who did not undergo liver transplantation were analyzed. Unadjusted and adjusted odds ratios (ORs) were calculated. RESULTS: Non-A-E-ALF constituted 34.6% (n = 538) of all ALF patients, whereas hepatitis E virus (HEV), hepatitis B virus (HBV), and anti-tuberculosis therapy (ATT) accounted for 29.5% (n = 459), 8.6% (n = 134), and 7.4% (n = 115), respectively. Among non-A-E-ALF patients, mean age was 28.8 ± 12.0 years, 50.9% females, majority (63.1%) had hyperacute presentation, and 79.2% had advanced encephalopathy at presentation. The frequency of cerebral edema in non-A-E-ALF (53.3%) was higher than that in HEV-ALF (41.2%) and ATT-ALF (44.2%), P < 0.001. The survival rate in non-A-E-ALF (37.5%) was poorer than HEV-ALF (54.9%) and was comparable to that in HBV (35.8%) and ATT (29.6%) induced ALF. The baseline prothrombin time prolongation (odds ratio [OR] 1.041; 95% confidence intervals [CI], 1.017-1.065) and infection (OR 2.366; 95%CI, 1.107-5.055) were independent predictors of outcome in non-A-E-ALF. The 3-days acute liver failure early dynamic model had the best value in predicting the outcome. CONCLUSIONS: Non-A-E-ALF accounts for one-third of all cases of ALF and is associated with poor spontaneous survival.
Authors: William Bernal; Anna Hyyrylainen; Amit Gera; Vinod K Audimoolam; Mark J W McPhail; Georg Auzinger; Mohammed Rela; Nigel Heaton; John G O'Grady; Julia Wendon; Roger Williams Journal: J Hepatol Date: 2013-02-22 Impact factor: 25.083
Authors: Javier Fernández; Juan Acevedo; Reiner Wiest; Thierry Gustot; Alex Amoros; Carme Deulofeu; Enric Reverter; Javier Martínez; Faouzi Saliba; Rajiv Jalan; Tania Welzel; Marco Pavesi; María Hernández-Tejero; Pere Ginès; Vicente Arroyo Journal: Gut Date: 2017-08-28 Impact factor: 23.059
Authors: S K Acharya; S Dasarathy; T L Kumer; S Sushma; K S Prasanna; A Tandon; V Sreenivas; S Nijhawan; S K Panda; S K Nanda; M Irshad; Y K Joshi; S Duttagupta; R K Tandon; B N Tandon Journal: Hepatology Date: 1996-06 Impact factor: 17.425
Authors: Fin Stolze Larsen; Lars Ebbe Schmidt; Christine Bernsmeier; Allan Rasmussen; Helena Isoniemi; Vishal C Patel; Evangelos Triantafyllou; William Bernal; Georg Auzinger; Debbie Shawcross; Martin Eefsen; Peter Nissen Bjerring; Jens Otto Clemmesen; Krister Hockerstedt; Hans-Jørgen Frederiksen; Bent Adel Hansen; Charalambos G Antoniades; Julia Wendon Journal: J Hepatol Date: 2015-08-29 Impact factor: 25.083